CLYM Climb Bio Inc: Forward P/S Multiple
Climb Bio Inc develops advanced therapies for complex inflammatory pathologies. P/S expectations for the company reflect market optimism, where the metric determines the status of the valuation parameter. Management strictly controls resources for antibody development. Business success is based on advancing budigalimab into late-stage trials and securing major partners.
Summary analytical data breakdowns for Climb Bio, Inc (CLYM)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- debt level and financial liquidity data:
- business earnings and investment ratios data:
CLYM - Net Financial Result|Expected Profit Climb Bio Inc|CLYM - Market Cap to Earnings|Projected Price to Earnings Climb Bio, Inc.|CLYM - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Climb Bio, Inc|CLYM - Operating income before deduction of amortization|Earnings per share for the last twelve months Climb Bio|CLYM - Earnings per share for the last 12 months|Quarterly EPS earnings growth climbbio.com|CLYM - Net earnings per share growth this year|Earnings growth forecast for next year Climb Bio Inc
- sales revenue and business income indicators:
Summary company analytics:Climb Bio (CLYM)
Climb Bio Inc (CLYM) ethical ESG standards in drug development mitigate regulatory risks, directly impacting the stability of future cash flows. The forward P/S ratio compares current market capitalization with expected revenue, allowing investors to assess the rate of multiple compression and the risk of a "value trap" in the event of declining demand, as illustrated on this chart.
Key competitors
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA Corp (ADMA) - Forward Price-to-Revenue Multiple|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|IMVT (immunovant.com) - Price-to-Projected Revenue Ratio|KNSA (Kiniksa) - Forward P/S Multiple|Grifols SA (GRFS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Forward Price-to-Revenue Multiple Celldex Corp CLDX|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|biocryst.com - Price-to-Projected Revenue Ratio|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics Inc)|PHVS: Forward P/S Multiple|ABCL (AbCellera Corp) - Price-to-Projected Revenue Ratio|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|precigen.com (PGEN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Pharming Group (PHAR)|NKTR - Market Cap to Future Revenue Ratio|Upstream Bio Corp - Forward Price-to-Revenue Multiple|Forward Price to Sales ZBIO|Immunome, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio gossamerbio.com GOSS|KalVista Pharmaceuticals, Inc. (KALV) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue SEPN|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Savara Pharma (SVRA)|Forward P/S Multiple RIGL|Forward Price-to-Revenue Multiple anaptysbio.com ANAB|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|enGene Holdings Inc - Price-to-Projected Revenue Ratio|RAPT: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Aerovate Therapeutics Inc|Aclaris Therapeutics (ACRS) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple kyvernatx.com|Price-to-Projected Revenue Ratio Tiziana Life Sciences Ltd|Cabaletta Bio Inc. - Future Price to Revenue|Forward P/S Multiple VTYX|THTX (Theratechnologies, Inc) - Forward Price to Sales|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc)|Forward P/S Multiple eledon.com ELDN|AGEN - Price-to-Projected Revenue Ratio|Forward Price to Sales ZURA (Zura Bio Ltd)|aTyr (ATYR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Adagene Inc.|IMA (ImageneBio) - Forward P/S Multiple|Forward P/S Multiple Shattuck Therapeutics|Forward Price-to-Revenue Multiple EQ (Equillium, Inc.)|CNTB (connectbiopharm.com) - Forward Price to Sales|Forward P/S Multiple IMUX (Immunic)|Market Cap to Expected Sales Ratio Atara Biotherapeutics, Inc. (ATRA)|IFRX - Price-to-Projected Revenue Ratio|x4pharma.com (XFOR) - Forward Price-to-Revenue Multiple|adicetbio.com (ACET) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Celularity|Forward Price-to-Revenue Multiple INMB|Forward P/S Multiple Barinthus Biotherapeutics Corp|Price-to-Projected Revenue Ratio Kezar Life Sciences (KZR)|sabbiotherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Enlivex Therapeutics Ltd (ENLV) - Market Cap to Future Revenue Ratio|Q32 Bio Corp - Forward P/S Multiple|GeoVax Corp (GOVX) - Forward Price-to-Revenue Multiple|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|IBIO (ibioinc.com) - Price-to-Projected Revenue Ratio|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|XTL Biopharmaceuticals Ltd (XTLB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|Forward Price-to-Revenue Multiple hcwbiologics.com HCWB|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|AIM ImmunoTech, Inc. - Price-to-Projected Revenue Ratio|ADTX: Forward Price-to-Revenue Multiple|Forward Price to Sales GRI (GRI Bio Inc)|XRTX: Forward P/S Multiple|HIND (Vyome Therapeutics) - Price-to-Projected Revenue Ratio|REVB (Revelation Biosciences) - Forward P/S Multiple|indaptusrx.com (INDP) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI - Market Cap to Future Revenue Ratio|Affimed N.V. - Forward Price-to-Revenue Multiple|Forward Price to Sales ALLK|HOOKIPA - Forward P/S Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue OCEA|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Third Harmonic Bio Inc (THRD)
